{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:34Z","timestamp":1793212114017,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1053\/j.gastro.2010.11.004","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T04:39:53Z","timestamp":1289363993000},"page":"425-434.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease"],"prefix":"10.1053","volume":"140","author":[{"given":"Andreas","family":"Tromm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bungani\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tomsov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Tulassay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Luk\u00e1\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kykal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"B\u00e1tovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohumil","family":"Fixa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Gabalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz\u2013Jochen","family":"Kramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Altorjay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"L\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Koutroubakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bar\u2013Meir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"\u0160timac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Sch\u00e4ffeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Mohrbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Greinwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2010.11.004_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohn Colitis"},{"key":"10.1053\/j.gastro.2010.11.004_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000296.pub3","article-title":"Budesonide for induction of remission in Crohn's disease","volume":"3","author":"Seow","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2010.11.004_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0090-9556(25)08073-0","article-title":"Metabolic pathways of the topical glucocorticoid budesonide in man","volume":"11","author":"Edsb\u00e4cker","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.gastro.2010.11.004_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2010.11.004_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0090-9556(25)06497-9","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"Jonsson","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.gastro.2010.11.004_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00054725-200409000-00012","article-title":"Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein","volume":"10","author":"Dilger","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2010.11.004_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1542-3565(04)00121-1","article-title":"Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion","volume":"2","author":"Feagan","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2010.11.004_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2010.11.004_bib9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/jcem-27-7-973","article-title":"Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay","volume":"27","author":"Murphy","year":"1967","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2010.11.004_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.21214","article-title":"Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver","volume":"44","author":"Meier","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2010.11.004_bib11","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2010.11.004_bib12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","article-title":"CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation","volume":"9","author":"Geisler","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.gastro.2010.11.004_bib13","series-title":"ADDPLAN\u2013adaptive designs, plans and analyses","year":"2007"},{"key":"10.1053\/j.gastro.2010.11.004_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.0006-341X.1999.01286.x","article-title":"Adaptive sample size calculations in group sequential trials","volume":"55","author":"Lehmacher","year":"1999","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2010.11.004_bib15","series-title":"Handbook of sequential analysis","first-page":"283","article-title":"Group sequential tests and repeated confidence intervals","author":"Jennison","year":"1991"},{"key":"10.1053\/j.gastro.2010.11.004_bib16","series-title":"CPMP\/EWP\/482\/99: points to consider on switching between superiority and non-inferiority","year":"2000"},{"key":"10.1053\/j.gastro.2010.11.004_bib17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2010.11.004_bib18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2010.11.004_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2010.11.004_bib20","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2010.11.004_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2010.11.004_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2010.11.004_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2010.11.004_bib24","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1873-9946(09)60210-5","article-title":"P183\u2013predictive factors for a mild course of Crohn's disease","volume":"3","author":"Bokemeyer","year":"2009","journal-title":"J Crohn Colitis"},{"key":"10.1053\/j.gastro.2010.11.004_bib25","first-page":"3124","article-title":"Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties","volume":"46","author":"Tromm","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.gastro.2010.11.004_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.clpt.6100505","article-title":"Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression","volume":"84","author":"Ufer","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2010.11.004_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2010.11.004_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0016-5085(00)70210-1","article-title":"High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy","volume":"118","author":"Farrell","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2010.11.004_bib29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2010.11.004_bib30","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2010.11.004_bib31","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1111\/j.1572-0241.2008.02176.x","article-title":"Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease","volume":"103","author":"Thia","year":"2008","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851001601X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851001601X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:56:11Z","timestamp":1758034571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851001601X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S001650851001601X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2010.11.004","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2010.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}